ANI PHARMACEUTICALS, INC Cash and Restricted Cash
ANI PHARMACEUTICALS, INC (ANIP) had Cash and Restricted Cash of $360.25 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $360.25M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $311.21M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $285.62M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $262.65M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $360.25M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $311.21M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $285.62M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $262.65M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $217.83M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $149.84M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $144.89M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $145.02M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $240.11M 10-Q · filed 2025-08-08 |
| 2024-03-31 | $228.60M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $221.12M 10-K · filed 2026-02-27 |
| 2023-09-30 | $193.08M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $161.71M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $67.76M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $53.23M 10-K · filed 2026-02-27 |
| 2022-09-30 | $61.28M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $68.39M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $81.91M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $105.30M 10-K · filed 2025-02-28 |
| 2021-09-30 | $20.25M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $29.26M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $30.07M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $12.87M 10-K · filed 2024-02-29 |
| 2020-09-30 | $22.90M 10-Q · filed 2021-11-01 |
| 2020-06-30 | $32.70M 10-Q · filed 2021-08-06 |
| 2020-03-31 | $25.42M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $67.36M 10-K · filed 2023-03-09 |
| 2019-09-30 | $64.70M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $45.61M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $43.24M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $48.03M 10-K · filed 2022-03-15 |
| 2018-09-30 | $49.15M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $60.00M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $56.97M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $36.15M 10-K · filed 2021-03-11 |
| 2017-09-30 | $23.04M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $13.37M 10-Q · filed 2018-08-07 |
| 2017-03-31 | $15.83M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $32.37M 10-K · filed 2020-02-27 |
| 2016-09-30 | $21.16M 10-Q · filed 2017-11-02 |
| 2016-06-30 | $20.02M 10-Q · filed 2017-08-03 |
| 2015-12-31 | $154.68M 10-K · filed 2019-02-27 |
| 2014-12-31 | $169.04M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |